Literature DB >> 24665982

Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.

Raquel P Deering1, Sushma Kommareddy, Jeffrey B Ulmer, Luis A Brito, Andrew J Geall.   

Abstract

INTRODUCTION: Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively evaluated in human clinical trials and have been shown to be safe and immunogenic, although none have been licensed for human use. More recently, mRNA-based vaccine alternatives have emerged and might offer certain advantages over their DNA-based counterparts. AREAS COVERED: This review describes the two main categories of mRNA vaccines: conventional non-amplifying and self-amplifying mRNA. It summarizes the initial clinical proof-of-concept studies and outlines the preclinical testing of the next wave of innovations for the technology. Finally, this review highlights the versatile functionality of the mRNA molecule and introduces opportunities for future improvements in vaccine design. EXPERT OPINION: The prospects for mRNA vaccines are very promising. Like other types of nucleic acid vaccines, mRNA vaccines have the potential to combine the positive attributes of live attenuated vaccines while obviating many potential safety limitations. Although data from initial clinical trials appear encouraging, mRNA vaccines are far from a commercial product. These initial approaches have spurred innovations in vector design, non-viral delivery, large-scale production and purification of mRNA to quickly move the technology forward. Some improvements have already been tested in preclinical models for both prophylactic and therapeutic vaccine targets and have demonstrated their ability to elicit potent and broad immune responses, including functional antibodies, type 1 T helper cells-type T cell responses and cytotoxic T cells. Though the initial barriers for this nucleic acid vaccine approach seem to be overcome, in our opinion, the future and continued success of this approach lies in a more extensive evaluation of the many non-viral delivery systems described in the literature and gaining a better understanding of the mechanism of action to allow rational design of next generation technologies.

Entities:  

Keywords:  delivery system; mRNA; mode of action; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24665982     DOI: 10.1517/17425247.2014.901308

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  45 in total

1.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

2.  Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

Authors:  Willy M Bogers; Herman Oostermeijer; Petra Mooij; Gerrit Koopman; Ernst J Verschoor; David Davis; Jeffrey B Ulmer; Luis A Brito; Yen Cu; Kaustuv Banerjee; Gillis R Otten; Brian Burke; Antu Dey; Jonathan L Heeney; Xiaoying Shen; Georgia D Tomaras; Celia Labranche; David C Montefiori; Hua-Xin Liao; Barton Haynes; Andrew J Geall; Susan W Barnett
Journal:  J Infect Dis       Date:  2014-09-18       Impact factor: 5.226

Review 3.  Micro- and nanoparticulates for DNA vaccine delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-04

Review 4.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

5.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Authors:  Michela Brazzoli; Diletta Magini; Alessandra Bonci; Scilla Buccato; Cinzia Giovani; Roland Kratzer; Vanessa Zurli; Simona Mangiavacchi; Daniele Casini; Luis M Brito; Ennio De Gregorio; Peter W Mason; Jeffrey B Ulmer; Andrew J Geall; Sylvie Bertholet
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

Review 6.  Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications.

Authors:  Siddharth Patel; Avathamsa Athirasala; Paula P Menezes; N Ashwanikumar; Ting Zou; Gaurav Sahay; Luiz E Bertassoni
Journal:  Tissue Eng Part A       Date:  2018-06-07       Impact factor: 3.845

Review 7.  Zika Virus Vaccine Development.

Authors:  Kaitlyn M Morabito; Barney S Graham
Journal:  J Infect Dis       Date:  2017-12-16       Impact factor: 5.226

Review 8.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Authors:  Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

Review 9.  The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Authors:  Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy
Journal:  Expert Rev Vaccines       Date:  2019-02-11       Impact factor: 5.217

10.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.